key: cord-0259856-2lss04fc
authors: Smith-Byrne, K.; Chen, Y.; Kachuri, L.; Kapoor, P. M.; Guida, F.; Zahed, H.; Alcala, K.; Amos, C.; Atkins, J.; Bodinier, B.; Ferreiro-Iglesia, A.; Hung, R. J.; Johansson, M.; Koh, W.-P.; Kyro, C.; Langhammer, A.; Pietzner, M.; Sala, N.; Sandanger, T. M.; Travis, R. C.; Tsilidis, K.; Yuan, J.-M.; Robbins, H.; Brennan, P.; McKay, J.; Malarstig, A.
title: IL-18 and Lower Risk for Lung Cancer: Triangulated Evidence from Germline Predictions, Pre-Diagnostic Measurements, and Tumor Expression
date: 2021-03-26
journal: nan
DOI: 10.1101/2021.03.26.21254400
sha: a6d46265204ce38c171864099b9035c400d24e60
doc_id: 259856
cord_uid: 2lss04fc

Lung cancer remains the most common cause of cancer death globally. Dysregulation of immune response and inflammatory signaling is known to play an important role in lung tumorigenesis, but the causal drivers of this process have yet to be elucidated. To identify circulating inflammatory and immune-related proteins that influence risk for lung cancer we related genetically predicted plasma levels for 85 inflammation and immune proteins with susceptibility to lung cancer. Mendelian randomization (MR) analyses in 29,266 cases and 56,450 controls identified a candidate causal marker, IL-18, which conferred lower risk of lung cancer (OR per standard deviation increase: 0.85 [95% CI: 0.79-0.92]), in particular for adenocarcinoma (OR: 0.80 [95% CI: 0.72-0.89]). We subsequently validated this association using polygenic IL-18 predictions in the UK Biobank (HR highest vs. lowest quartile: 0.83 [95% CI: 0.72-0.95]) and using pre-diagnostic blood concentrations of IL-18 in 732 cases and 732 controls after controlling for the inhibitory role of IL-18BP (OR highest vs. lowest quartile: 0.63 [95% CI: 0.41-0.91]). Genetic colocalization suggested that IL-18 may act on lung cancer risk locally via lung tissue expression, and joint MR and tumor microenvironment analyses highlight CD8 T cells and NK cells as potential mediators. In addition to risk, IL-18 expression in adenocarcinoma tumor tissue was found to be associated with all-cause mortality in 480 TCGA samples after controlling for IL-18BP (HR per SD: 0.87 [95% CI: 0.78, 0.98]), which is in line with recent studies showing anti-tumor effects of IL-18. Our comprehensive genomic triangulation study thus highlights the potential for IL-18 as an aetiological biomarker and targetable for immune-oncology therapies.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

Lung cancer is the third most highly incident cancer and the leading cause of cancer death globally 1 . While tobacco exposure accounts for most lung cancer diagnoses 2 , a majority of lung cancers in western countries are now diagnosed among former and never smokers 3 . Identifying novel aetiological and modifiable risk factors that aid the prevention of lung cancer is therefore important and should be prioritised.

The role of inflammation in lung cancer aetiology, such as IL-6 4,5 , IL-8 5 and the IL-1 beta pathway 6 , presents an attractive potential target for chemoprevention due to their role in tissue remodelling and homeostasis 7 , cell proliferation 8 , and angiogenesis 9 . However, despite consistent observational evidence for the role of specific inflammation and immune-related proteins 4, 5, 10 , the confounding role of smoking and other biases not well-remedied through traditional epidemiology have precluded the identification of an aetiological role for inflammation in lung cancer aetiology.

Modern molecular epidemiology may overcome such concerns by integrating evidence from multiple, independent, lines of evidence drawn from study designs with differing sources of bias, such as Mendelian Randomisation (MR), welldesigned prospective studies, and patient tumor characteristics -an approach commonly referred to as triangulation 11, 12 . MR leverages common genetic variation to instrument the association of an exposure (such as inflammatory protein levels)

with an outcome (lung cancer). The random segregation of alleles at conception requires that genetic variation be assigned prior to disease onset and substantially . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ;  https://doi.org/10.1101/2021.03.26.21254400 doi: medRxiv preprint reduces the influence of biases that plague classical epidemiology. Nonetheless, MR remains sensitive to a number of assumptions, such as horizontal pleiotropy where a genetic instrument may associate with the outcome via both an exposure of interest and an alternative exposure like smoking. In the case of proteins, such bias may be alleviated by using genetic variation located adjacent to its coding gene that influence circulating concentrations by affecting transcription or translation 13 . Where analyses also preclude confounding by linkage disequilibrium (LD), MR represents a strong complementary source of evidence for the discovery of novel aetiological factors. For instance, a protein associated with lung cancer risk using MR and a welldesigned prospective epidemiological study, with additional support from tumour characteristics (e.g. gene expression, gene-specific mutation etc), would provide compelling evidence for a role in aetiology not likely explained by a single source of confounding, such as tobacco exposure.

We aimed to identify novel inflammation and immune-related proteins in lung cancer aetiology. Following an initial MR-based discovery analysis, we sought to triangulate promising protein-risk signals using polygenic protein predictions in an independent large prospective cohort, direct pre-diagnostic measurements from a case-control study, and molecular and immune cell characteristics from patient tumor samples.

An overview of the study design is shown in Figure 1 . Our objective was to identify aetiological inflammation and immune-related proteins for lung cancer risk using complementary sources of data. Based on genetic instruments identified in a protein GWAS of 30,913 individuals, we initially conducted an exploratory two-sample MR using a large GWAS to identify candidate proteins. Proteins with support from MR . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 26, 2021. ;  after sensitivity and colocalization analyses, were evaluated in relation to the tumor immune microenvironment to assess potential pathways using both MR and estimated tumor immune characteristics among lung cancer patients. Subsequently, we sought additional support for the importance of promising proteins with lung cancer using polygenic predicted protein concentrations in the UK Biobank, direct measurements in pre-diagnostic blood from a case-control study nested in six large population cohorts, and tumor gene expression for promising proteins with patient prognosis in the Cancer Genome Atlas 14 (TCGA). STROBE-MR 15 and STROBE 16 reporting guidelines were followed. 

Of the 90 proteins assayed in 30,931 individuals with genome-wide genotyping data, 85 circulating proteins had SNPs associated at genome-wide significance (P<5x10 -8 ), of which 74 had cis-protein quantitative trait (pQTL)s located within 1mb of the protein-coding gene. Only SNPs that were independent (linkage disequilibrium, r 2 > . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.26.21254400 doi: medRxiv preprint 0.01) from other SNPs for a given protein, and with no significant heterogeneity of SNP effects across the 14 studies contributing to GWAS meta-analysis were included in further analyses. After data harmonization, 85 proteins with 366 unique SNPs, including 129 cis-pQTL, were included in analyses. There was no overlap of participants between the protein and lung cancer GWAS samples.

In MR analysis to describe the association between proteins and risk for lung cancer, for proteins with one available robust pQTL SNP available we used Wald estimates (β cancer /β protein ), and for proteins with multiple pQTL SNPs per-SNP Wald estimates were combined using the inverse-variance weighted approach (IVW). A false discovery rate (FDR) of 5% was applied to define a p-value threshold corrected for multiple testing to identify promising risk proteins for downstream analyses.

We performed quantitative and qualitative sensitivity analyses to evaluate potential violations of MR assumptions. For proteins with FDR significant Wald/IVW estimates, we ran weighted-median 19 , MR-PRESSO 20 , and MR-Egger 21 sensitivity analyses that provide estimates more robust to bias from horizontal pleiotropy and can quantify net directional pleiotropy (using the MR-Egger intercept). Heterogeneity of the SNP estimates-an indication of horizontal pleiotropy-was evaluated using Cochran's and Rücker's Q 22 . Subsequently, we consulted all phenotypes in the OpenGWAS 23 catalogue to identify potential horizontal pleiotropy for pQTL instruments used in main MR analyses. As an additional assessment of pleiotropy, we conducted a proteome-wide association analysis across 4,979 proteins (multiple testing correction, p<1e-5) for the cis and trans pQTL used to estimate risk associations for proteins otherwise passing sensitivity analyses. These analyses were in 8,350 participants using linear regression adjusted for age, sex, center, and the first ten genetic principal components (data not shown) within the Fenland study 24 .

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.26.21254400 doi: medRxiv preprint

For proteins passing these MR sensitivity analyses and with available cis-pQTL (i.e. SNPs in or within 1Mb of the protein-coding gene), a separate MR analysis was conducted using the Wald ratio to estimate risk. Further, we performed colocalization 25, 26 analyses to evaluate confounding due to linkage disequilibrium using a 75kb region up-and downstream of a given cis-pQTL. Bidirectional MR was used to estimate potential lung cancer effects on protein concentrations as a sensitivity analysis to assess the correct orientation of MR estimates.

To evaluate the influence on the tumor immune landscape for the promising lung cancer proteins identified through MR, we conducted analyses using both MR and individual level patient tumor characteristics based on patients within TCGA. To conduct MR analyses, summary statistics for each of the cis and trans pQTL used in the main risk analyses were extracted for tumor immune characteristics from a recent pan-cancer GWAS that included ~9,000 cancer patients from 30 cancer subtypes from TCGA 27 . All MR methods applied were as described above. Analyses is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.26.21254400 doi: medRxiv preprint for age at diagnosis, sex, smoking status, and tumor stage were used to estimate the association of gene expression with tumor immune characteristics.

We used polygenic predictions (PRS) calculated using the LDPred algorithm 28 to estimate the association for promising proteins with lung cancer risk using individuallevel data from the UK Biobank. PRS typically explain a greater proportion of the variance for protein concentrations than GWAS significant hits. Therefore, they may be better powered to discover associations with the caveat that they cannot be understood as causal estimates, but rather as a complementary analysis to MR in independent individual-level samples. The UK Biobank is a large ongoing prospective cohort, from 2006, with more than 500,000 participants described in Bycroft et al. 29 and accessed under project number 15825 (Supplementary Methods). Cox regression was used to estimate the association of genetically predicted protein concentrations with lung cancer risk in UK Biobank. All models were adjusted for age, genotyping array, and the first five principal components of ancestry, and stratified by sex. Sensitivity analyses were also stratified by smoking status.

To evaluate the association between directly measured blood protein levels and lung cancer risk, we used data on circulating concentrations of 85 proteins using the Olink platform in 732 lung cancer cases and 732 matched controls based on smoking status that were available within a parallel lung cancer early detection project (U19 CA203654). Conditional logistic regression models were used to estimate the association of proteins with lung cancer risk adjusting for age, body-mass index, and additional smoking characteristics (cigarettes per day and years smoked) and . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

The association of tumor gene expression in lung cancer patients with all-cause mortality in TCGA was estimated using Cox-regression to time from diagnosis to death as an underlying time variable. Models were additionally adjusted for age at diagnosis and stratified by sex, smoking status, and tumor-stage. Statistical analyses were performed using R (TwoSampleMR 30 , Coloc 25 ; hyprcoloc 26 , The R project 31 ).

In the initial MR analyses of 85 proteins for lung cancer risk, at an FDR threshold of 5%, we discovered an association with lung cancer risk for interleukin 18 (IL-18, N SNP =6 [5 trans and 1 cis], variance explained:4.3%, Figure 2 ). This association remained after pleiotropy-robust analyses: weighted median and MR-PRESSO and was directionally concordant using MR-Egger regression (eTable2). As specified a priori, IL-18 was therefore the only protein further investigated. A genetically 

Little evidence was found to support colocalization for lung cancer overall (11%), small cell (1.7%), or squamous cell carcinoma (1.3%). However, there was moderate support for colocalization between IL-18 protein levels and risk for adenocarcinoma (colocalization probability 64%). To investigate further whether an association of IL-18 with adenocarcinoma acts via expression of IL-18 in lung tissue we additionally . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Polygenic predicted IL-18 (LDPred Score, variance explained:24%) was available for 326,583 UK Biobank participants that had no overlap with either the IL-18 protein or lung cancer GWAS, of whom 1,605 had been diagnosed with incident lung cancer. 

Data from 732 cases and 732 matched controls identified within six prospective cohorts were included in the analysis. For cases, the mean time between prediagnostic blood collection and diagnosis was 1.6 years (IQR:0.8-2.4 years) (eTable11).

Base model conditional logistic regressions showed a positive association for direct pre-diagnostic blood measurements of IL-18 with lung cancer risk (OR highest vs. It is well known that IL18BP is a natural IL-18 inhibitor, affecting maturation and concentration of bioactive IL-18, which determines IL-18-stimulated immune . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ;  responses via the IFN-γ pathway 32 . Therefore, we expect IL-18 to have a biological effect only when it is at a concentration greater than IL-18BP. This would ideally be modelled by a simple ratio, however, log2 relative quantification of proteins, as is available using the Olink platform, with differing natural abundancies do not allow for this ratio to be interpretable. Accordingly, we modeled the inhibitory effect of IL-18BP on IL-18 using an interaction term between IL-18BP and IL- 18 Figure 3 ).

We sought to identify novel inflammation-related proteins with a role in lung cancer aetiology by integrating results from large-scale GWAS, prospective cohorts, and tumor genomic analyses. The initial MR analysis queried 85 proteins and identified an inverse relation between IL-18 and lung cancer risk, and downstream analyses . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Specifically, we carried out an initial discovery analysis using MR to identify putative causal biomarkers, which revealed an estimated 15% reduction in lung cancer risk per standard deviation increase in IL-18 plasma levels. We also provide evidence that this association may act on risk locally via expression in lung tissue and potentially mediated by influencing the abundance of CD8 T cells and NK cells in the tumor microenvironment. The lung cancer susceptibility signal was validated in two prospective studies and one case-series using both genetically predicted and directly measured IL-18 levels. Polygenically predicted IL-18 in UK Biobank found a 17% lower risk for lung cancer among individuals with high IL-18. Similarly, direct IL-18 measurements in pre-diagnostic bloods were associated with a 37% reduced risk for lung cancer after accounting for the well-documented IL-18 inhibitory effects of IL-18BP. Lastly, we identified a 13% lower risk for all-cause mortality for higher IL-18 lung tumor tissue expression in adenocarcinoma patients after accounting for IL-18BP. These independent lines of evidence clearly indicate that IL-18 has an important role in mediating lung carcinogenesis.

IL-18 is a member of the IL-1 family, a group of 11 pro-and anti-inflammatory cytokines that are activated by NLRP3 37 , NLRP1 38 and NLRC4 inflammasomes 39 . IL-18 drives MYD88 signaling 32 , which has been found to stimulate macrophages 40 , Th1 cells 33,34 , CD8 T cells and NK cells 32 , and drives interferon-gamma response 36 .

We replicated the association of IL-18 with these immune characteristics using independent MR and tumor gene expression analyses finding evidence for an association for IL-18 expression with these immune cells local to lung tumor tissue.

Colocalization of IL-18 pQTL with risk for lung cancer and lung tissue IL-18 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ;  expression was largely explained by the minor allele for the lead cis-pQTL/eQTL (rs5744249, 52%). Interestingly, we are believed to have introgressed this IL-18 elevating allele from Neandertals 41 , and so the protective effect of IL-18 may reflect immune response inherited from early homonid interbreeding 42 .

Therapeutically recombinant IL-18 (rIL-18) has a synergistic role with immune checkpoint inhibitors 43 and may up-regulate immune pathways for tumorigenesis and progression 44 . However, even though rIL-18 is well-tolerated by patients in clinical trials 45 , it has been difficult to demonstrate the clinical utility of rIL-18. This has been attributed primarily to the negative regulatory role of IL-18BP in the bioactivity of circulating IL-18 46 . Indeed, a recent study that found IL-18 engineered as insensitive to IL-18BP has strong and consistent effects on T cell and NK cell activation in mouse tumors and acted to inhibit tumor progression 32 . It is therefore a strength of this study that no significant pleiotropy for IL-18 instruments was observed with IL-18BP implying our genetic MR discovery analyses was not affected by genetically higher IL-18BP. Further, based on the negative regulatory effect for IL-18BP on IL-18, it is in line with our current understanding of IL-18 function that an inverse association with lung cancer risk using direct measurements and all-cause mortality using tumor tissue expression was only observed after accounting for the inhibitory effect of IL-18BP.

Nonetheless, our study design was not without limitation. Firstly, pre-diagnostic blood measurements for IL-18 were among former and current smoking cases with a relatively short time between recruitment and diagnosis (max:3 years), which cannot protect against reverse-causation and precludes generalizing findings to never smokers. Further, the lack of treatment information available in TCGA did not allow us to explore the interplay between IL-18 tumor expression and survival by modern . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ;  treatments known to act on potential IL-1 pathways, such as PD-L1 inhibitors.

However, a re-analysis of CANTOS trial data found no association for the promising IL-1 beta antagonist Canakinumab for the reduction of IL-18 47 , which may imply IL-18 acts on risk for lung cancer via an alternative pathway to IL-1 beta.

In summary, we report multiple lines of evidence supporting a protective role of IL-18 in lung cancer aetiology. IL-18 may act to inhibit tumorigenesis via CD8 T and NK cell count local to lung tissue which is in line with the current understanding for IL-18 function. Altogether, these results highlight the potential for IL-18 as an aetiological biomarker for lung cancer and potential target for immune-oncology therapies.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 1 . Overall study design. The objective of this study was to identify support for inflammation and immune-related proteins involved in the aetiology of lung cancer using a Mendelian randomization (MR) discovery subsequently triangulated using complementary evidence from independent source of data. In the MR discovery we find strong statistical support for the association of IL-18 with risk for lung cancer. Additionally, colocalization analyses may suggest that the association for IL-18 and lung cancer my act via expression in lung tissue. Following the MR discovery, we sought support for IL-18 and lung cancer risk using polygenic genetic IL-18 predictions in the UK Biobank, pre-diagnostic blood measurement in a large . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ;  prospective nested case-control, and patient tumor characteristics and all-cause mortality. In these data we found broad support for IL-18 and lung cancer risk and patient mortality, albeit only after taking into account the inhibitory effect of IL-18BP for blood and tumor measurements. Additional MR and individual-level analyses for the association of IL-18 with tumor immune characteristics highlight CD8 T cells and NK cells as potential intermediate phenotypes. 

cis-pQTL to cancer risk cis-pQTL to lung cis-eQTL cis-pQTL to lung cis-eQTL to cancer risk

Association between genetic predictions for IL-18 and pan-cancer tumor immune characteristics (MR) and for tumor expression and these characteristics in lung adenocarcinoma patients (480) in TCGA

Association of polygenic predicted IL-18 (LDPred) with risk for lung cancer incidence (1,605) using Cox-regression

Association of pre-diagnostic blood concentrations of IL-18 with lung cancer risk nested in six large prospective cohorts (732 cases, 732 controls) using conditional logistic regression

Association of IL-18 tumor expression and all-cause mortality among 480 adenocarcinoma patients (192 deaths) in TCGA using Cox-regression DISCOVERY TRIANGULATION Figure 1 .

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

GLOBOCAN 2012 v 1.0, cancer incidence and mortality worldwide: IARC CancerBase No. 11

Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study

Global epidemiology of lung cancer. Ann Glob Heal

C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis. Cancer Causes Control

Inflammatory Cytokines and Lung Cancer Risk in 3 Prospective Studies

Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity

Interleukin-6: Designing specific therapeutics for a complex cytokine

Interleukins as modulators of angiogenesis and anti-angiogenesis in tumors

Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

Triangulation in aetiological epidemiology

Robust research needs many lines of evidence

Selecting instruments for Mendelian randomization in the wake of genome-wide association studies

The cancer genome atlas pancancer analysis project

Guidelines for strengthening the reporting of Mendelian randomization studies

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nat Metab

Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes

Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator

Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases

Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression

Improving the visualization, interpretation and analysis of two-sample summary data Mendelian randomization via the Radial plot and Radial regression

The MRC IEU OpenGWAS data infrastructure

Genetic architecture of host proteins involved in SARS-CoV-2 infection

Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics

A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits

Germline genetic contribution to the immune landscape of cancer

Modeling Linkage Disequilibrium Increases Accuracy of Polygenic Risk Scores

The UK Biobank resource with deep phenotyping and genomic data

The MR-base platform supports systematic causal inference across the human phenome. Elife

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

Cloning of a new cytokine that induces IFN-γ production by T cells

Interleukin-18 regulates both Th1 and Th2 responses

Interleukin-18 amplifies macrophage polarization and morphological alteration, leading to excessive angiogenesis

Unique action of Interleukin-18 on T cells and other immune cells. Front Immunol

The NLRP3 inflammasome: An overview of mechanisms of activation and regulation

The NLRP1-IL18 Connection: A Stab in the Back of Obesity-Induced Inflammation

Distinct Roles of IL-1β and IL-18 in NLRC4-Induced Autoinflammation. Front Immunol

Direct stimulation of macrophages by IL-12 and IL-18 -A bridge too far?

Impacts of Neanderthal-Introgressed Sequences on the Landscape of Human Gene Expression

Multiple episodes of interbreeding between Neanderthal and modern humans

Augmentation of immune checkpoint cancer immunotherapy with IL18

IL-18 induces PD-1-dependent immunosuppression in cancer

Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer

Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines

This research was supported by funding from the US National Institutes of Health (INTEGRAL Program grant U19 CA203654) and Cancer Research UK (C18281/A29019). We would additionally like to acknowledge the SCALLOP and ILCCO consortia for generating the extensive summary statistics making the discovery analysis possible.